A phase I trial of in vivo gene therapy with the herpes simplex thymidine kinase/ganciclovir system for the treatment of refractory or recurrent ovarian cancer.
A phase I trial of in vivo gene therapy with the herpes simplex thymidine kinase/ganciclovir system for the treatment of refractory or recurrent ovarian cancer.
复制标题
使用单纯疱疹胸苷激酶/更昔洛韦系统进行体内基因治疗治疗难治性或复发性卵巢癌的 I 期试验。
作者：
C. Link;D. Moorman;T. Seregina;J. Levy;K. Schabold
本研究将评价PA317/LTKOSN.2载体产生细胞(VPC)体内转导单纯疱疹病毒胸苷激酶(HStk)基因治疗复发或难治性卵巢癌的安全性和有效性。将HStk基因插入肿瘤细胞使其对抗疱疹药物更昔洛韦(GCV)具有敏感性。HStk/GCV系统可诱导旁观者效应和抗肿瘤免疫反应。HStk VPC已经摧毁了在动物体内生长的腹膜肿瘤。这种对正在生长的原位肿瘤的选择性破坏被认为是由于肿瘤内产生有毒的GCV代谢物所致。这一过程导致了毒性有限的实验动物的治愈。因此，我们建议将这项技术应用于难治性或复发性卵巢癌的治疗。患有复发或难治性卵巢癌的成年女性(≥18岁)在进入研究之前将接受疾病范围和部位(S)的评估。帕特。
III. Scientific Abstract This study will evaluate the safety and efficacy of in vivo gene transfer of the Herpes Simplex-thymidine kinase (HStk) gene using PA317/LTKOSN.2 vector producing cells (VPC) in patients with recurrent or refractory ovarian cancer. Insertion of the HStk gene into tumor cells confers a sensitivity to the anti-herpes drug ganciclovir (GCV). The HStk/GCV system induces a bystander effect and an anti-tumor immune response. HStk VPC have destroyed intraperitoneal tumors growing in animals. This selective destruction of growing tumors in situ is thought to result from the production of toxic GCV metabolites within the tumor. This procedure has resulted in the cure of experimental animals with limited toxicity. Therefore, we propose to apply this technique for the treatment of refractory or relapsed ovarian cancer. Adult women (≥18 years) with recurrent or refractory ovarian cancer, will be evaluated for the extent and location(s) of their disease before being entered into the study. Pat...
恶性脑肿瘤逆转录病毒基因治疗的实验模型。
影响因子：
4.1
作者：
Takamiya,Y;Short,MP;Moolten,FL;Fleet,C;Mineta,T;Breakefield,XO;Martuza,RL
通讯作者：
Martuza,RL